Melanocortin Receptor Agonist
Melanotan I
BioHarmony verdict
Worth trying
Melanotan I is most defensible for photoprotection in EPP and planned UV exposure, with Langendonk 2015 reporting 69.4 vs 40.8 hours of pain-free sun exposure in the US trial. The wellness case is narrower than the prescription afamelanotide evidence.
Read full reportWhat is Melanotan I?
Melanotan I (Afamelanotide) is a synthetic MC1R-selective alpha-MSH analog with prescription-grade evidence for erythropoietic protoporphyria, where Langendonk reported 69.4 versus 40.8 hours of pain-free sun exposure in the US Phase III arm. Afamelanotide works by increasing eumelanin through MC1R, which explains why the upside is strongest for photoprotection and pigment-related use cases. Melanotan I earns a worth-trying score because regulated SCENESSE has meaningful human evidence and the intrinsic afamelanotide safety profile is manageable with dermatology monitoring.
From the BioHarmony report, reviewed 2026-09-08.
How it is thought to work
MC1R activation increases eumelanin and UV tolerance
Safety watch-outs
- New or rapidly changing mole, oral pigmentation, or bleeding lesion
- Severe headache, confusion, vision change, chest pain, or neurologic symptoms
- Priapism, severe abdominal pain, dark urine, or muscle pain after dosing
Full risk profile in the BioHarmony report.
Dosing as published
No approved-label or study protocol is recorded for Melanotan I yet.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Educator coverage (2)
Attributed viewpoints, separate from primary research.
- International Peptide Society 2018 Compound CurriculumDr. William Seeds · 2018-07-20
- Melanotan 1 vs Melanotan 2: Which Peptide Is Right for You?Jay Campbell · 2026-05-19
Trust & sourcing
Primary sources
Sources are still being reviewed for this compound.
Related peptides for skin & hair
Free guide
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.